Strength Seen in 4D Molecular Therapeutics (FDMT): Can Its 7.9% Jump Turn into More Strength?
4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics, Inc. (FDMT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
4D Molecular Therapeutics, Inc. (FDMT) Presents at Jefferies Global Healthcare Conference 2026 Transcript
4DMT to Participate in Upcoming Investor Conferences
4D Molecular Therapeutics, Inc. (FDMT) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
4D Molecular Therapeutics Touts Rapid Phase 3 Momentum for Retinal Gene Therapy
4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics, Inc. (FDMT) Presents at Bank of America Global Healthcare Conference 2026 Transcript
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates
4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
4DMT to Participate in Upcoming Investor Conferences
4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics (NASDAQ:FDMT) versus TransCode Therapeutics (NASDAQ:RNAZ) Head-To-Head Contrast
4D Molecular Therapeutics, Inc. $FDMT Shares Sold by Assenagon Asset Management S.A.
4D Molecular Therapeutics (NASDAQ:FDMT) Shares Gap Up Following Analyst Upgrade
4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates
4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
4DMT to Participate in Upcoming Investor Meetings
4D Molecular Therapeutics, Inc. (FDMT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
4D Molecular Therapeutics, Inc. (FDMT) Presents at TD Cowen 46th Annual Health Care Conference Prepared Remarks Transcript
4DMT to Participate in Upcoming Investor Conferences
4DMT Announces New Employment Inducement Grants
4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD
4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics, Inc. (FDMT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Contrasting NLS Pharmaceutics (NASDAQ:NCEL) and 4D Molecular Therapeutics (NASDAQ:FDMT)
4DMT Provides Company Update and Anticipated Development Milestones for 2026
4D Molecular Therapeutics (NASDAQ:FDMT) Insider Sells $17,821.50 in Stock
4D Molecular Therapeutics, Inc. (FDMT) Discusses Interim Phase I Data From AEROW Trial in Cystic Fibrosis and Platform Potential Transcript
4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease
4DMT Announces New Employment Inducement Grants
4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference
4D Molecular Therapeutics, Inc. (FDMT) Presents at Jefferies London Healthcare Conference 2025 Transcript
4DMT to Participate in 8th Annual Evercore Healthcare Conference
4DMT Appoints Kristian Humer as Chief Financial Officer
4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates
4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
4DMT to Participate in Jefferies 2025 London Healthcare Conference
4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants
4DMT Announces Positive Long-Term Data from Phase 1/2 PRISM Clinical Trial in Wet AMD Supporting 4D-150's Potential as a Backbone Therapy with Consistent and Durable Benefit over Multiple Years
4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific
4DMT Announces New Employment Inducement Grants
Wall Street Analysts See a 208.52% Upside in 4D Molecular Therapeutics (FDMT): Can the Stock Really Move This High?
4DMT to Participate in Chardan's 9th Annual Genetic Medicines Conference
4DMT Advances 4D-710 to Phase 2 with Additional Funding and Support from the Cystic Fibrosis Foundation
4D Molecular Therapeutics: This Gene Therapy Company May Soon Surprise Investors
4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics, Inc. (FDMT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)